Putting in vitro platforms at the heart of cardiotoxicity testing
Tuesday, July 13, 2021 from 2-3pm (BST)
This webinar forms part of the CRACK IT 10 year anniversary celebrations and will showcase the technologies and platforms developed to address the 2013 InPulse CRACK IT Challenge to develop a human-based in vitro system to assess cardiotoxicity in new drugs. The Challenge was sponsored by GlaxoSmithKline (GSK).
The InPulse CRACK IT Challenge aimed to develop a physiologically relevant cardiac contractility platform to identify early in development novel drugs with potential cardiovascular (CV) safety liabilities, one of the most common causes of drug attrition. Multiple different technologies and platforms were developed or advanced to meet this technically demanding challenge. These include three-dimensional engineered heart tissues, fully functional human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and a new software platform for the measurement of cardiomyocyte and cardiac muscle contraction. Different lines of hiPSC-CMs, in combination with different platform technologies, were each tested using the same set of compounds provided by the Sponsor. Using this approach it was possible to establish the optimum configuration to assess the cardiotoxic potential of drugs with a focus on cardiac contractility. A typical investigative animal study to assess cardiac contractility of drugs prior to clinical trials would use at least 12 – 24 dogs. Applying the developed in vitro platforms early in drug development could significantly reduce these numbers.
During the webinar, which is free to attend, you will hear from the project leader of the InPulse Challenge and the Sponsor who supported the development and validation of the platforms. There will be an opportunity to ask questions after the webinar presentation.